This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features!

Skip to main page content

Add to Collections

Your saved search

Name of saved search:

Search terms:

Test search terms

Would you like email updates of new search results?

Yes
No

Email: (change)

Frequency:

Which day?

Which day?

Report format:

Send at most:

Send even when there aren't any new results

Optional text in email:

Your RSS Feed

Editorial

. 2018 Mar 20;36(9):835-836.

doi: 10.1200/JCO.2017.76.9885. Epub 2018 Feb 1.

How Should We Assess Benefit in Patients Receiving Checkpoint Inhibitor Therapy?

Bartosz Chmielowski¹

Affiliations

PMID: 29389232
DOI: 10.1200/JCO.2017.76.9885

Editorial

How Should We Assess Benefit in Patients Receiving Checkpoint Inhibitor Therapy?

Bartosz Chmielowski. J Clin Oncol. 2018.

. 2018 Mar 20;36(9):835-836.

doi: 10.1200/JCO.2017.76.9885. Epub 2018 Feb 1.

Author

Bartosz Chmielowski¹

Affiliation

¹ Bartosz Chmielowski, University of California Los Angeles, Jonsson Comprehensive Cancer Center, Los Angeles, CA.

PMID: 29389232
DOI: 10.1200/JCO.2017.76.9885

No abstract available

PubMed Disclaimer

Comment on

Immune-Modified Response Evaluation Criteria In Solid Tumors (imRECIST): Refining Guidelines to Assess the Clinical Benefit of Cancer Immunotherapy.
Hodi FS, Ballinger M, Lyons B, Soria JC, Nishino M, Tabernero J, Powles T, Smith D, Hoos A, McKenna C, Beyer U, Rhee I, Fine G, Winslow N, Chen DS, Wolchok JD. Hodi FS, et al. J Clin Oncol. 2018 Mar 20;36(9):850-858. doi: 10.1200/JCO.2017.75.1644. Epub 2018 Jan 17. J Clin Oncol. 2018. PMID: 29341833

Publication types

Actions
Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions

Substances

Actions

LinkOut - more resources

Full Text Sources
- Atypon
- Ovid Technologies, Inc.
Other Literature Sources
- scite Smart Citations